There is only limited data on the prevalence of epidermal growth factor receptor (EGFR) activating mutations in squamous cell carcinomas and adenosquamous carcinomas of the lung in patients of the Southern Bulgarian region and the effi cacy of EGFR tyrosine kinase inhibitors. AIM: Previous reports for Bulgarian population showed high incidence of EGFR mutations in the squamous cell carcinomas, so we set the goal to investigate their frequency in Southern Bulgaria, after precise immunohistochemical verifi cation of lung cancers. MATERIALS AND METHODS: Two hundred and thirty-six lung carcinomas were included in this prospective study. All biopsies were initially analysed with p63, TTF1, Napsin A, CK7, CK34βE12, synaptophysin, CK20 and CDX2. Two hundred and twenty-fi ve non-small cell lung carcinomas were studied with real-time PCR technology to assess the status of the EGFR gene. RESULTS: We detected 132 adenocarcinomas (58.7%), 89 squamous cell carcinomas (39.2%), 4 adenosquamous carcinomas (1.8%), 9 large cell neuroendocrine carcinomas (3.8%) and 2 metastatic colorectal adenocarcinomas (0.8%). Activating mutations in the EGF receptor had 3 out of 89 squamous cell carcinomas (3.37%). We have established mutations in L858R, deletion in exon 19 and rare mutation in S7681. One out of four adenosquamous carcinomas had a point mutation in the L858R (25%). CONCLUSIONS: The frequency of EGFR mutations we found in lung squamous cell carcinomas in a Southern Bulgarian region is lower than that in European countries. Ethnic diversity in the region does not play role of an independent predictive factor in terms of mutation frequency. Medica 2015;57(3&4):191-199 Copyright © 2015 Medical University, Plovdiv РЕЗЮМЕ Почти отсутствуют данные о частоте данных мутаций при плоскоклеточных и аденосквамозных карциномах у пациентов из Южной Болгарии, а также об эффективности терапии ингибиторами эпидермального фактора роста. ЦЕЛЬ: Так как предыдущие исследования болгарских популяций показывают высокую частоту мутаций эпидермального фактора роста при плоскоклеточных карциномах, мы поставили своей задачей исследование данной частоты в популяциях из Южной Болгарии после точной иммунной гистологической верификации опухоли лёгких. МАТЕРИАЛЫ И МЕТОДЫ: В проспективное исследование было включено 236 карциномов лёгких. Все биопсии были протестированы p63 TTF1, Napsin А, CK7, CK34βE12, Synaptophysin, CK20 и CDX2. Для оценки состояния гена эпидермального фактора роста было исследовано 225 случаев немелкоклеточной карциномы лёгких при помощи полимеразной цепной реакции в реальном времени. РЕЗУЛЬТАТЫ: Установлены 132 аденокарциномы (58.7%), 89 плоскоклеточных карцином (39.2%), 4 аденосквамозные карциномы (1.8%), 9 крупноклеточных нейроэндокринных карцином (3.8%) и 2 метастазные колоректальные аденокарциномы (0.8%). Наличие активирующих мутаций в рецепторе эпидермального фактора роста установлено в трёх из 89 плоскоклеточных карцином (3.37 %). Установлены мутации в L858R, делеция в 19 экзоне и редкая мутация в S7681. На каждые четыре аденосквамозные карциномы приходится одна с точечной мутацией в L858R (25 %). Выводы: Наблюдаемая частота мутаций эпидермального фактора роста плоскоклеточных карцином лёгких в Южной Болгарии ниже по сравнению с другими европейскими странами. Этническое разнообразие в регионе не играет роли независимого фактора, предсказывающего частоту подобных мутаций.
INTRODUCTION
Non-small cell lung carcinomas (NSCLC) are approximately 85% of newly diagnosed cancers of the lung, with two major histological subtypes: approximately 50% are adenocarcinomas (AC) and 30% squamous cell carcinomas (SCC). Lung SCC is closely associated with tobacco smoking (up to 400 000 deaths per year, according to the WHO statistics). 1 The discovery of the so-called "driver mutations", such as the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) rearrangements has led to remarkable improvement in the personalized therapy of lung adenocarcinoma. 2, 3 Efforts at conservative therapy are aimed primarily at ACs, since there is currently no personalized therapy for the SCCs.
Whole exon/genome sequencing of lung SCC allows identifi cation of several potential mutations in the signaling pathways. These are FGFR1 amplifi cations, PI3K/ACT mutations, PTEN mutations/ deletions, PDGFRA mutations, as well as DDR2 mutations. The transition to personalized therapy can be a step forward in discovering these potential biomarkers for the treatment of lung SCC. 3, 4 However, no such available molecular target exists for lung carcinomas with squamous cell histology at present. Therapies with bevacizumab, pemetrexed and EGFR tyrosine-kinase inhibitors have been developed for lung adenocarcinomas, but are contraindicated or largely ineffective in lung SCC. Patients with lung SCC are treated with one-sizefi ts-all platinum-based chemotherapy. 5, 6 Adenosquamous (ADSQ) lung carcinoma contains components of both, squamous cell carcinoma and adenocarcinoma, the proportion of each of them being no less than 10% of the tumor mass. It is a rare subtype, accounting for 0.4 to 4% of all NSCLC. Because of its rarity, clinicopathological characteristics of ADSQ carcinomas have not been adequately studied, and its pathogenesis is still unclear. The general prognosis of this tumor is worse than that of AC and SCC. 7 In recent years in two large prospective studies of NSCLC in Bulgaria, Damyanov D. et al. reported 9.4% incidence of EGFR mutations in 752 patients with lung cancer. 8, 9 In the group of activating EGFR mutations positive patients (n = 71), the prevalence of adenocarcinomas was 59.7% (43/71). It is worth noting that EGFR mutations occurred relatively frequently in squamous cell carcinoma patients (33.9%, 24/71). These results, however, were reported without immunohistochemical analysis. This is perhaps the reason why the mutations found in squamous cell carcinomas are far more frequent than those reported by other authors whose studies have been conducted on an adequate number of cases. 10, 11, 19 The considerable discrepancy in the reported data could be due to differences in the methodology of performing the mutation analysis, but could be also a result of genetic differences between eastern patient populations and other populations. 7 Such ethnic diversity can be found, to a certain extent, in Southern Bulgaria, which makes it necessary to compare these data with data from other regions of the country.
AIM
The aim of the present study was a detailed histological and immunohistochemical categorization of non-small cell lung carcinomas with EGFR mutations in patients in Southern Bulgaria having in mind the ethnic diversity in the region. Carcinomas which demonstrated neuroendocrine differentiation (synaptophysin positive) or were metastatic colorectal adenocarcinomas (CK20 and CDX2 positive), a total of 11 cases, were not subjected to a genetic study. The biopsy material was analyzed immunohistochemically in the laboratory of the Medical University in Plovdiv using two markers -p63 and TTF1, and PAS reaction for mucin. Double negative tumors were in addition verifi ed with Napsin A, CK7, CK34βE12, synaptophysin, CK20 and CDX2.
DNA EXTRACTION, EGFR GENE MUTATION ANALYSIS Molecular analysis was performed at the National Genetic Laboratory, Sofi a. Two hundred and twentyfi ve biopsy samples of primary lung carcinomas were studied for EGFR mutations. Tested samples were taken from paraffi n-embedded, surgical and endoscopic biopsies. For DNA analysis we selected only the cases with more than 50% tumour cells in the sections, employing 10 cuts of 5 μm. For the EGFR gene mutation analysis we used the Scorpions Amplifi cation Refractory Mutation System (SARMS) technology (Qiagen). The ARMS PCR technology combined with the Scorpions detection technology provides fast and reliable technology for detection of mutations in FFPET. This method is more sensitive and specifi c for detection of known mutations than dideoxy sequencing technology. The specifi cally designed EGFR RGQ PCR kit allows the detection of 29 known recurrent mutations (including the inhibitory mutation T790M) in exons 18-21 of the EGFR gene, including 19 deletions in exon 19 (does not distinguish between them), T790M in exon 20, L858R in exon 21, L861Q in exon 21, G719X in exon 18 (G719S, G719A or G719C, but does not distinguish between them), S768I in exon 20 and 3 insertions in exon 20 (does not distinguish between them). The various reactions were performed according to the manufacturer's instructions and the analyses were carried out for all the samples as described in the kit instruction manual. A Rotor-Gene Q MDx machine was used for performing the PCR reactions.
RESULTS
Out of the 225 cases with NSCLC in patients from Southern Bulgaria, 132 (58.7%) were found to be AC, 89 (39.2%) -SCC and four cases (1.8%) -ADSQ. Thirteen cases (5.77%) were found to be positive for EGFR mutation. Nine (3.99%) of these tumours were classic adenocarcinomas (Table 1) . In three patients the mutations involved the L858R region. Four were with deletion in exon 19. Only one positive patients was of ethnic Turkish origin -a female, non-smoker, with adenocarcinoma and rare mutation in L861Q (Table 1 , Case 4).
In the group with EGFR mutations in the SCC (3/89, 3.37%) the patients were predominantly male, active and former smokers with 30-40 pack years (Fig. 2) . The genetic study was positive for EGF receptor mutation in L858R. 
DISCUSSION
EGFR and KRAS mutations are oncogenic aberrations that are highly prevalent in adenocarcinomas but extremely rare in squamous cell carcinomas. Squamous cell carcinomas more often display changes in the signalling pathways of PI3K/AKT and tyrosinekinase receptors, including EGFR amplifi cation, as well as BRAF mutations or FGFR amplifi cation or mutations (in 69% of samples). Loss-of-function mutations and mutations in HLA-A class I major histocompatibility gene have been found in 3% of tumours, which suggests a possible role of genotypic selection of patients for immunotherapies such as anti-programmed death 1 (PD1) and anti-cytotoxic T-lymphocytic antigen 4 (CTLA4). 12 ADSQ lung carcinomas are rare histological 17 The discrepancy could be due to differences in the methodology used in mutation analysis but could also be a result of genetic differences between Eastern populations and other populations. 7 We are interested in a recent pilot study among the Turkish population, where EGFR mutations in SCC patients were found in more than half of the studied tumours (54.5%, 6 out of 11), which is consistent with the prevalence rate reported in Asian populations. 18 (Table 3) .
Miyamae Y, et al. examined 89 squamous cell lung carcinomas for EGFR mutations in exons 19 and 21. The initial prevalence was 5.6%, all with deletion in exon 19. Immunohistochemical analysis with р63, TTF-1 and staining for mucin using Alcian Blue demonstrated an adenomatous component in two of the tumours. Thus, the percentage of positive SCC was reduced to 3.4% (3/87). The researchers found a small yet signifi cant number of positive mutations in squamous cell carcinomas, which justifi ed the genotyping of all NSCLC, making the diagnostic process even more accurate and giving chance to such patients to be treated with TKI therapy. 11 The EGFR mutations we found in the large sample size SCC are consistent with the data of these authors (3.37%), while the highest positivity rates in ADSQ carcinomas (25%) is not informative, since due to the small number of studied cases. The overall incidence of mutations in all cancers are found to be lower than the mean prevalence in European population and only one patient of a different ethnic origin was found to have activating mutations. In our study ethnic diversity in Southern Bulgaria is not an independent prediction factor for higher mutation frequency of EGFR in SCC and ADSQ carcinomas.
Analysis of the mutations and their correlation with etiologic and morphogenetic factors lead to contradictory conclusions: Sasaki et al. reported that mutational status of EGFR -ADSQ carcinoma signifi cantly correlated with smoking history and gender. 13 Kang et al. found that EGFR mutations in ADSQ carcinoma patients were more common 20, 21 Although the pathogenesis of ADSQ carcinomas has not yet been elucidated, similar molecular characteristics such as DNA aneuploidy, loss of heterozygosity and genomic alterations of p53 and K-RAS have been found in both adenomatous and squamous cell carcinomatous components. 14 The fact that, in our single observation, the squamous cell component was benign, i.e. it was an adenoacanthoma, is in favour that the two cell lines might derive from a common precursor cell. Under specifi c effect of these mutations, the progenitor cells could develop into both types of tumour cells. The presence of identical mutations in both tumour cells components could explain the monoclonality of carcinogenesis pathway. This is also supported by recent larger sample studies in which 27-40% of patients with ADSQ carcinomas harboured EGFR-activating mutations. 16 The fi rst expectation of EGFR mutations in Europe is carried out by Powrozek T. et al. (2014) , in patients of Polish origin. Activating mutations of EGFR were observed in 28.6% (four out of 14) of ADSQ carcinoma-bearing patients and shows that the percentage of EGFR mutations detected in ADSQ carcinoma patients was comparable to or even higher than the percentage of EGFR mutations reported in adenocarcinoma cases. 19 The three squamous cell carcinomas and the one ADSQ carcinoma, positive for EGFR gene mutations, constitute 1.78% of all researched NSCLC patients from Southern Bulgaria. These data agree with the results of other authors who examined all NSCLC for EGFR mutations. Liam CK et al. consider that pure squamous cell lung carcinomas lacking any adenocarcinoma component, ЕGFR mutations positive, have a prevalence of less than 5%. 24 EGFR mutations in exons 19 and 21 are useful molecular markers to predict the response to EGFR-TKI therapy. Patients with EGFR mutations have a response rate of approximately 70%, and an overall survival of 30.5 months. And yet, a recent pooled analysis of published reports showed that the prognosis for lung carcinoma patients harbouring EGFR-sensitive mutations and receiving TKI therapy differs for adenocarcinoma patients and for non-adenocarcinoma patients. The latter group included patients with ADSQ carcinoma. 26 The cumulative fi ve-year postoperative survival rate of ADSQ carcinoma patients was found to be approximately 20%, which makes it worse than that of patients with adenocarcinoma or squamous cell carcinoma (40% for both groups). 22 Unlike these authors, Paik P et al. 23 found an equal response to TKI therapy in AC and ADSQ carcinoma patients with activating EGFR mutations, 12 months progression-free survival and a median overall survival of 29 months.
Tokumo M, et al. 21 found that 69% of the patients with adenocarcinoma responded to TKI therapy, and had a median progression-free survival of 9.8 months, while among the patients with non-adenocarcinomas of the lungs response rate to therapy was 35%, and median progression-free survival -only 3.1 months. The reported two cases with ADSQ carcinomas had a stable response to TKI therapy for three years. 21 In the present study patients with SCC receiving TKI therapy had a different response rates. In Case 1, the patient was less affected by target therapy and made progression and rapid deterioration after 4 months. The patient in Case 2 was stabilized at 19 months of treatment with tyrosine kinase inhibitors with partial reduction of lung cancer and bone metastases.
CONCLUSION
The EGFR mutations in non-adenocarcinoma patients are one of the negative prediction values for the effect of treatment with EGFR inhibitors of tyrosine kinase (EGFR-TKI). 26 However, in some cases the therapy had been effective and patients had a very good response. Good response of therapy depends on the stage of the disease and the clinical performance.
The results of this study support the view of the International Association for the Study of Lung Cancer and the Association for Molecular Pathology that lung cancer patients should not be excluded from genetic study on the basis of clinical characteristics that include ethnicity, smoking history and gender. 24 We extend this view with the recommendation that genetic studies should not exclude smokers with SCC or ADSQ carcinomas of the lung, giving them the chance to receive an adequate personalized therapy.
